Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint Immunotherapy

Part # PS290

Abstract

Jamison Grailer, Pete Stecha, Julia Gilden, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

Immunotherapy aims to boost a patient’s own immune system to fight disease. Activation of T cells via direct stimulation of the T cell receptor or by modulating immune checkpoint pathways are two strategies being employed individually and in combination. Immune checkpoint targets include co-inhibitory (e.g. PD-1, CTLA-4, TIGIT, LAG-3) and co-stimulatory (e.g. GITR, 4-1BB, OX40, CD40) receptors. Here we describe the application of cell-based reporter bioassays for the development of therapeutic antibodies targeting co-inhibitory immune checkpoint receptors.

Printed in USA.